{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:03:53Z","timestamp":1786935833399,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cllc.2025.08.008","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T23:09:44Z","timestamp":1756336184000},"page":"e708-e723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics of Epidermal Growth Factor Receptor-Mutant Nonsmall-Cell Lung Cancer Patients Benefiting From Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"26","author":[{"given":"Haodi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiyu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Pang","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-He","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8663-3161","authenticated-orcid":false,"given":"Shao-Huan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2025.08.008_bib0001","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: Cancer J Clin"},{"key":"10.1016\/j.cllc.2025.08.008_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.cllc.2025.08.008_bib0003","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.3390\/biomedicines11112916","article-title":"Hope and challenges: immunotherapy in EGFR-mutant NSCLC patients","volume":"11","author":"Yan","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.cllc.2025.08.008_bib0004","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future","volume":"4","author":"Chan","year":"2015","journal-title":"Transl Lung Cancer"},{"key":"10.1016\/j.cllc.2025.08.008_bib0005","article-title":"PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol"},{"issue":"18","key":"10.1016\/j.cllc.2025.08.008_bib0006","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cllc.2025.08.008_bib0007","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.08.008_bib0008","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.lungcan.2020.06.032","article-title":"Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: the phase II ATLANTIC study","volume":"147","author":"Garassino","year":"2020","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.cllc.2025.08.008_bib0009","first-page":"l5460","article-title":"Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis","volume":"367","author":"Zhao","year":"2019","journal-title":"BMJ (Clinical Res Ed)"},{"issue":"1","key":"10.1016\/j.cllc.2025.08.008_bib0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cllc.2025.08.008_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.602762","article-title":"Development of EGFR TKIs and options to manage resistance of third-generation EGFR TKI Osimertinib: conventional ways and immune checkpoint inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2025.08.008_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.926890","article-title":"Efficacy of immune checkpoint inhibitors in EGFR-mutant NSCLC patients with EGFR-TKI resistance: a systematic review and meta-analysis","volume":"13","author":"Qian","year":"2022","journal-title":"Front Pharmacol"},{"issue":"22","key":"10.1016\/j.cllc.2025.08.008_bib0013","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cllc.2025.08.008_bib0014","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/1346-8138.17445","article-title":"Comparison of efficacy between anti-PD-1 antibody monotherapy and nivolumab plus ipilimumab therapy as first-line immunotherapy for advanced mucosal melanoma in Japanese patients: a single-center, retrospective cohort study","volume":"51","author":"Horisaki","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.cllc.2025.08.008_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1385425","article-title":"Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study","volume":"14","author":"Gupta","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2025.08.008_bib0016","article-title":"Evaluation of the efficacy and safety of first- and second-line immunotherapy in patients with metastatic colorectal cancer: a systematic review and network meta-analysis based on randomized controlled trials","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.cllc.2025.08.008_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1137464","article-title":"Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis","volume":"14","author":"Liang","year":"2023","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.cllc.2025.08.008_bib0018","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1186\/s12885-024-13058-z","article-title":"Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2025.08.008_bib0019","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3389\/fphar.2018.01430","article-title":"The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis","volume":"9","author":"Ma","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cllc.2025.08.008_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.739090","article-title":"Front-line ICI-based combination therapy post-TKI resistance may improve survival in NSCLC patients with EGFR mutation","volume":"11","author":"Tian","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2025.08.008_bib0021","first-page":"338","article-title":"[Analysis of the efficacy of immunotherapy on the posterior lines of advanced EGFR mutant patients with non-small cell lung cancer]","volume":"24","author":"Ma","year":"2021","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"10","key":"10.1016\/j.cllc.2025.08.008_bib0022","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis","volume":"25","author":"Zhao","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.08.008_bib0023","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clnesp.2025.03.023","article-title":"Prognostic significance of the cachexia index (CXI) in patients with cancer: a systematic review and meta-analysis","volume":"68","author":"Bas","year":"2025","journal-title":"Clin Nutr ESPEN"},{"issue":"21","key":"10.1016\/j.cllc.2025.08.008_bib0024","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.3390\/cancers16213689","article-title":"Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis","volume":"16","author":"Sahin","year":"2024","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.cllc.2025.08.008_bib0025","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/CAD.0000000000001118","article-title":"Role of PD-L1 assessment in advanced NSCLC: does it still matter?","volume":"32","author":"Rizzo","year":"2021","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.cllc.2025.08.008_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103119","article-title":"Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma","volume":"156","author":"Lamberti","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.cllc.2025.08.008_bib0027","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00262-020-02662-0","article-title":"Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors","volume":"70","author":"Ichihara","year":"2021","journal-title":"Cancer Immunol Immunother: CII"},{"key":"10.1016\/j.cllc.2025.08.008_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832419","article-title":"Efficacy of immune checkpoint inhibitors in patients with EGFR mutated NSCLC and potential risk factors associated with prognosis: a single institution experience","volume":"13","author":"Bai","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.cllc.2025.08.008_bib0029","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00432-024-05618-4","article-title":"Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-lung-003 prospective observational registry study","volume":"150","author":"Kuribayashi","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.cllc.2025.08.008_bib0030","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.cllc.2025.08.008_bib0031","unstructured":"Wells G.S.B, O\u2019Connell D., et al. The Newcastle\u2013Ottawa scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Ottawa Hospital Research Institute: Ottawa, ON, Canada, 2012. Available online: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"10.1016\/j.cllc.2025.08.008_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1217872","article-title":"Real-world study of PD-1\/L1 immune checkpoint inhibitors for advanced non-small cell lung cancer after resistance to EGFR-TKIs","volume":"13","author":"Wei","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2025.08.008_bib0033","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00262-023-03370-1","article-title":"Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer","volume":"72","author":"Morimoto","year":"2023","journal-title":"Cancer Immunol Immunother: CII"},{"issue":"5","key":"10.1016\/j.cllc.2025.08.008_bib0034","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3892\/mco.2023.2634","article-title":"Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumor\u2011infiltrating CD68\u2011positive cell counts in patients with EGFR\u2011mutant non\u2011small cell lung cancer","volume":"18","author":"Tsuda","year":"2023","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.08.008_bib0035","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12890-023-02466-9","article-title":"Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations","volume":"23","author":"Si","year":"2023","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.cllc.2025.08.008_bib0036","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cam4.2037","article-title":"Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer","volume":"8","author":"Yamada","year":"2019","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.cllc.2025.08.008_bib0037","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1038\/s41598-024-54557-0","article-title":"Neutrophil to lymphocyte ratio may predict efficacy of anti-PD-1 inhibitors in advanced EGFR-mutant non-small cell lung cancer: retrospective cohort study","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.cllc.2025.08.008_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215292","article-title":"Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations","volume":"14","author":"Sato","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.cllc.2025.08.008_bib0039","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdz141","article-title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","volume":"30","author":"Hastings","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2025.08.008_bib0040","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/annonc\/mdx183","article-title":"Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment","volume":"28","author":"Haratani","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2025.08.008_bib0041","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/1759-7714.13346","article-title":"Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC","volume":"11","author":"Ishii","year":"2020","journal-title":"Thorac Cancer"},{"issue":"22","key":"10.1016\/j.cllc.2025.08.008_bib0042","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.3390\/cancers15225450","article-title":"Real-world outcomes of immunotherapy in second- or later-line non-small cell lung cancer with actionable genetic alterations","volume":"15","author":"Jun","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.cllc.2025.08.008_bib0043","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s00432-022-04125-8","article-title":"Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study","volume":"149","author":"Hata","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2025.08.008_bib0044","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cllc.2020.12.015","article-title":"Subtypes of EGFR- and HER2-mutant metastatic NSCLC influence response to Immune checkpoint inhibitors","volume":"22","author":"Lau","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"10.1016\/j.cllc.2025.08.008_bib0045","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1111\/1759-7714.13689","article-title":"Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs","volume":"11","author":"Yang","year":"2020","journal-title":"Thorac Cancer"},{"issue":"23","key":"10.1016\/j.cllc.2025.08.008_bib0046","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.08.008_bib0047","article-title":"Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.cllc.2025.08.008_bib0048","doi-asserted-by":"crossref","first-page":"6700","DOI":"10.3390\/curroncol29090526","article-title":"Immunogenic cell death role in urothelial cancer therapy","volume":"29","author":"Yadollahvandmiandoab","year":"2022","journal-title":"Curr Oncol (Toronto, Ont)"},{"issue":"3","key":"10.1016\/j.cllc.2025.08.008_bib0049","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.cllc.2025.08.008_bib0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2018.08.028","article-title":"Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"issue":"9","key":"10.1016\/j.cllc.2025.08.008_bib0051","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.cllc.2025.08.008_bib0052","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"Pt A","key":"10.1016\/j.cllc.2025.08.008_bib0053","article-title":"Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a two-center retrospective study","volume":"89","author":"Yao","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"15","key":"10.1016\/j.cllc.2025.08.008_bib0054","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res"},{"issue":"Pt 2","key":"10.1016\/j.cllc.2025.08.008_bib0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.semcancer.2018.06.002","article-title":"The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer","volume":"52","author":"Missiaen","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1016\/j.cllc.2025.08.008_bib0056","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/1759-7714.14267","article-title":"Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer","volume":"13","author":"Ito","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2025.08.008_bib0057","article-title":"Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.cllc.2025.08.008_bib0058","first-page":"392","article-title":"[Research progress in immune checkpoint inhibitors combination therapy applied to non-small cell lung cancer after EGFR mutation-targeted therapy resistance]","volume":"26","author":"Li","year":"2023","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.cllc.2025.08.008_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107933","article-title":"Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen","volume":"195","author":"Liu","year":"2024","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"5","key":"10.1016\/j.cllc.2025.08.008_bib0060","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/jcsm.13032","article-title":"The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer","volume":"13","author":"Song","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.cllc.2025.08.008_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.688625","article-title":"The role of tumor inflammatory microenvironment in lung cancer","volume":"12","author":"Tan","year":"2021","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.cllc.2025.08.008_bib0062","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.62347\/FEVG6730","article-title":"A comparative study of the efficacy and safety of PD-1\/L1 inhibitor and platinum-containing dual-agent chemotherapy in patients with advanced non-small cell lung cancer resistant to EGFR-TKIs","volume":"16","author":"Shi","year":"2024","journal-title":"Am J Transl Res"},{"issue":"17","key":"10.1016\/j.cllc.2025.08.008_bib0063","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25179276","article-title":"Proteomic investigation of immune checkpoints and some of their inhibitors","volume":"25","author":"Agostini","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cllc.2025.08.008_bib0064","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1084\/jem.20022235","article-title":"PD-1 inhibits antiviral immunity at the effector phase in the liver","volume":"198","author":"Iwai","year":"2003","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.cllc.2025.08.008_bib0065","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.cllc.2025.08.008_bib0066","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/pds.5487","article-title":"Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice","volume":"31","author":"Shah","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.cllc.2025.08.008_bib0067","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3892\/mco.2024.2730","article-title":"Clinical predictors of response to single\u2011agent immune checkpoint inhibitors in chemotherapy\u2011pretreated non\u2011small cell lung cancer","volume":"20","author":"Musaelyan","year":"2024","journal-title":"Mol Clin Oncol"},{"issue":"34","key":"10.1016\/j.cllc.2025.08.008_bib0068","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2012resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425001998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425001998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T04:23:33Z","timestamp":1763699013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425001998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1525730425001998"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.08.008","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of Epidermal Growth Factor Receptor-Mutant Nonsmall-Cell Lung Cancer Patients Benefiting From Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}